GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soleno Therapeutics Inc (NAS:SLNO) » Definitions » Inventory Turnover

Soleno Therapeutics (Soleno Therapeutics) Inventory Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Soleno Therapeutics Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Soleno Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil. Soleno Therapeutics's Average Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Soleno Therapeutics Inventory Turnover Historical Data

The historical data trend for Soleno Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soleno Therapeutics Inventory Turnover Chart

Soleno Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Soleno Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Soleno Therapeutics Inventory Turnover Calculation

Soleno Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Inventory Turnover (A: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2023 ) / ((Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

Soleno Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover (Q: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Dec. 2023 ) / ((Total Inventories (Q: Sep. 2023 ) + Total Inventories (Q: Dec. 2023 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Soleno Therapeutics  (NAS:SLNO) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Soleno Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory =Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=0/0*365 / 4
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Soleno Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Soleno Therapeutics Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Soleno Therapeutics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Soleno Therapeutics (Soleno Therapeutics) Business Description

Traded in Other Exchanges
Address
203 Redwood Shores Parkway, Suite 500, Redwood City, CA, USA, 94065
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome.
Executives
Patricia C Hirano officer: See Remarks 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Kristen Yen officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
Bhatnagar Anish director, officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
James H Mackaness officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Abingworth Bioventures Vii Lp 10 percent owner PRINCES HOUSE, 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Carlyle Holdings I L.p. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Sub L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505

Soleno Therapeutics (Soleno Therapeutics) Headlines

From GuruFocus

Soleno Therapeutics Announces Financing Commitment for up to $60 Million

By Value_Insider Value_Insider 12-19-2022